Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Read Why Demand For Pfizer's COVID-19 Antiviral Therapy Is Unexpectedly Low: Reuters

Global demand for Pfizer Inc's (NYSE:PFE) Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters review of data and interviews with experts has found.

Amid a recent rise in COVID-19 infections, Paxlovid supply far outstripped demand in the U.S., the U.K., Japan, and South Korea, data from health ministries and Reuters interviews with doctors and pharmacists found.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.